Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx
The Laryngoscope · 2025
DOI: 10.1002/lary.31786 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Laryngoscope, 2025. Verfasst von Ahmed I Ghanem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, Michigan, U.S.A. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Carcinoma in Situ. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare survival endpoints in patients with laryngeal carcinoma in situ (L‐CIS) who received definitive radiotherapy (RT) versus other modalities as first‐line treatment and after disease recurrence.
Methods
This is a retrospective study of patients with L‐CIS treated between June 2001 and December 2021. Survival outcomes (recurrence‐free (RFS), invasion‐free (IFS), laryngectomy‐free (LFS), and overall survival (OS)) were compared between patients who had first‐line RT versus non‐RT modalities and for patients with recurrent disease who underwent second‐line RT.
Results
A total of 85 patients with L‐CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55–74] years). Of these, 42 had first‐line RT (49.4%) and 43 (50.6%) had non‐RT treatment. After median follow‐up of 4.8 (IQR: 2.8–9) years, patients in the first‐line RT group had improved 2‐year (94.2% [95% confidence interval (CI): 86.7–100] versus 41.7% [CI: 29.3–59.5]) and 5‐year (90.6% [CI: 80.9–100] versus 27.5% [CI: 16.4–48.2]) RFS relative to non‐RT recipients ( p < 0.001). OS and IFS were similar between groups. However, patients in the RT group had worse 2‐year (94% [CI: 87–100] versus 98% [CI: 93–100]) and 5‐year (82% [CI: 68–99] versus 98% [CI: 93–100]; p = 0.013) LFS. All 35 patients with recurrent L‐CIS were successfully cured with second‐line treatments (12 received RT [34.3%]), and no differences in any survival endpoints were seen in these patients based on first‐line and second‐line treatments.
Conclusion
Although first‐line RT for L‐CIS led to improved recurrence‐free survival compared with other modalities, second‐line RT may be a particularly valuable option for recurrent CIS. Level of Evidence 3 Laryngoscope , 135:779–786, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, Michigan, U.S.A.
- Clinical Oncology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, U.S.A.
- Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, Michigan, U.S.A.
- Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, Michigan, U.S.A.
ORCID-Profile: Ahmed I Ghanem, Christian E Keller, Ross Mayerhoff
Zitieren
APA
I Ghanem, A., Gilbert, M., Lin, C. H., Keller, C. E., Gardner, G. M., Mayerhoff, R., & Siddiqui, F. (2025). Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx. The Laryngoscope. https://doi.org/10.1002/lary.31786
Vancouver
I Ghanem A, Gilbert M, Lin CH, Keller CE, Gardner GM, Mayerhoff R, et al. Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx. The Laryngoscope. 2025. doi:10.1002/lary.31786
BibTeX
@article{IGhanem2025,
author = {I Ghanem, Ahmed and Gilbert, Marissa and Lin, Chun-Hui and Keller, Christian E and Gardner, Glendon M and Mayerhoff, Ross and Siddiqui, Farzan},
title = {Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.31786}
}
EUVIMED